Director, Biostatistics Laboratory
Eric Polley, PhD is an Associate Professor in the Department of Public Health Sciences at The University of Chicago where he is the faculty director for the Data Science concentration in the Master of Public Health program. Dr. Polley was previously an Assistant Professor of Biostatistics in the Department of Quantitative Health Sciences at Mayo Clinic (2015-2021) and a mathematical statistician in the Biometric Research Branch at the U.S. National Cancer Institute (2012-2015). Dr. Polley received his PhD in biostatistics from the University of California, Berkeley in 2010. With Mark van der Laan, they developed the Super Learner ensemble prediction methodology. His research area involves the development and evaluation of prediction methods, innovative methods for diagnostic and prognostic prediction, and precision medicine clinical trial design.
National Cancer Institute
MD
Fellow - Computational Biology
2012
University of California, Berkeley
CA
PhD - Biostatistics
2010
Columbia University
NY
MS - Biostatistics
2005
Saint John's University
MN
BA - Mathematics
2003
GLP-1RA Use and Thyroid Cancer Risk.
GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngol Head Neck Surg. 2025 Mar 01; 151(3):243-252.
PMID: 39847346
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast. Clin Cancer Res. 2025 Jan 06; 31(1):130-138.
PMID: 39513960
Pathogenic variants in cancer susceptibility genes predispose to Ductal Carcinoma In situ of the breast.
Pathogenic variants in cancer susceptibility genes predispose to Ductal Carcinoma In situ of the breast. Clin Cancer Res. 2024 Nov 08.
PMID: 39513960
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
PMID: 39472970
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer. J Oncol Pharm Pract. 2024 Oct 13; 10781552241289581.
PMID: 39397422
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population. medRxiv. 2024 Oct 12.
PMID: 39417132
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clin Diabetes. 2025; 43(1):59-70.
PMID: 39829688
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. medRxiv. 2024 Sep 04.
PMID: 39281752
An electronic health record (EHR)-based risk calculator can predict fractures comparably to FRAX: a proof-of-concept study.
An electronic health record (EHR)-based risk calculator can predict fractures comparably to FRAX: a proof-of-concept study. Osteoporos Int. 2024 Dec; 35(12):2117-2126.
PMID: 39147872
Clinical Prediction Models in Neurocritical Care: An Overview of the Literature and Example Application to Prediction of Hospital Mortality in Traumatic Brain Injury.
Clinical Prediction Models in Neurocritical Care: An Overview of the Literature and Example Application to Prediction of Hospital Mortality in Traumatic Brain Injury. Neurocrit Care. 2025 Feb; 42(1):32-38.
PMID: 39107660
NCI Director's award for the development of the NCI-MATCH clinical trial
National Cancer Institute
2015